Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
These most often include major weight gain, altered hormone levels, morning nausea, and disturbed sleep patterns. In more extreme cases, symptoms can include labor pains, fatigue, postpartum depression, and nosebleeds. The labor pain symptom is commonly known as sympathy pain. The source of Couvade syndrome is a matter of debate.
Abdominal pain, also known as a stomach ache, is a symptom associated with both non-serious and serious medical issues. Since the abdomen contains most of the body's vital organs, it can be an indicator of a wide variety of diseases.
Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year. And now it stands ready to take the stage on its own.
“There are many medications that may cause weight gain,” says W. Scott Butsch, M.D., director of obesity medicine in the Bariatric and Metabolic Institute at the Cleveland Clinic.
The majority of low back pain does not have a clear cause [1] but is believed to be the result of non-serious muscle or skeletal issues such as sprains or strains. [31] Obesity, smoking, weight gain during pregnancy, stress, poor physical condition, and poor sleeping position may also contribute to low back pain. [31]
Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The company in July forecast sales of the drug to fall this year ...
Thiazolidinediones may cause slight weight gain but decrease "pathologic" abdominal fat (visceral fat), and therefore may be prescribed for diabetics with central obesity. [115] Thiazolidinedione has been associated with heart failure and increased cardiovascular risk; so it has been withdrawn from the market in Europe by EMA in 2010. [116]